Jump to content

All Activity

This stream auto-updates

  1. Today
  2. Have many people lost, weight because of IBS?
  3. Yesterday
  4. Last week
  5. Hi Sharon128, I have IBS-M (mixed) and IBD, but mine is Crohn's colitis - in my colon. It's treated like UC since many of the Crohn's meds - besides biologics - don't reach the sigmoid or rectum area, but the UC ones do. I went from IBS-D to IBS-M over the years. Often IBS-M becomes IBS-C so I can relate. I'll admit that all of the IBS-C medication research excluded anyone with IBD, so you are a unique snowflake in the IBS-C world. What is your doctor recommending?
  6. On this special episode of Tuesday Night IBS, we talk with the co-principal investigator, Alex Ford, MD, from Leeds University in the UK, about the ATLANTIS trial of Amitriptyline for irritable bowel syndrome (IBS) in primary care, which was funded by the Health Technology Assessment program of the National Institute for Health and Care Research and the TRITON trial using Ondansetron to manage irritable bowel syndrome with diarrhea. Dr. Alex Ford is a Professor and Honorary consultant gastroenterologist at St. James’s University Hospital, Leeds, UK. His main interest is in the epidemiology, diagnosis, and treatment of disorders of gut-brain interaction, such as irritable bowel syndrome and functional dyspepsia. He is an Associate Editor for Alimentary Pharmacology & Therapeutics. He has published over 450 peer-reviewed articles, including original scientific papers in The Lancet, JAMA, BMJ, Gastroenterology, Gut, Archives of Internal Medicine, and The American Journal of Gastroenterology.
  7. I was diagnosed with IBD, Ulcerative Colitis, over 25 years ago. I've had a relatively mild case, with periodic flare ups over the years. Recently, I was diagnosed with IBS-C, having the bloating, pains, blood and periodic constipation symptoms that were just enough different from my UC for me to look further into. (Cause UC for 25 years wasn't enough fun). I tried to find out if anyone in this group had the combo 1-2 punch of IBD with IBS-C but i could not find any titles that sounded like it. Just wondering if anyone else can relate. The challenges of this newer IBS-C dx are much harder than my IBD 😞.
  8. I have had IBS-C for four years. It has ruined my life. I don't know if my condition is just naturally worse than others, or if I made it worse by using so much mag cit, but I've had enough. I had a cholecystectomy a month ago and it was a success with one exception, the constipation got worse. The surgeon said my surgery was successful because I have biliary dyskinesia, and that surgery is the preferred one to help with that condition. So many of my other symptoms (I feel like I had a dozen at that point) left me except that one. I actually didn't believe that one problem could get worse. I spoke to my PA (The gastroenterologist doesn't work with me directly and looked upset with me when the PA requested a visit with her) and she ordered a anorectal manometry (sp?) to determine if my pelvic floor muscles are working. I'll then do PT for those muscles to see if I can get them to work again. If it fails, I guess that's when I begin talks with a surgical team to see if they will do a colostomy. I've done some research on it. It's extreme, the pain afterwards is supposed to be epic for two weeks, and there is some messy maintenance of the area. I can live with that. Anything is better than what I'm dealing with now. Those that got to my point, where they requested it, say that the positives greatly outweigh the negatives. The people I watched on YouTube actually look happy. I've been miserable for the last two years of this nightmare. But I need my schedule back. I can barely work now. Has anyone else considered this? Am I just being crazy or giving up too soon? I'd be interested to hear from any and all, but especially from those who may have had it done, or doctors who may be able to advise me on this.
  9. Dear IBS Patient, I had the great privilege of attending another Digestive Disease Week medical conference in May to learn about the latest research surrounding IBS and other digestive diseases. This year was especially meaningful as I was accompanied by several other IBS Patient Advocates; Rebecca Kaplan @rebeccakaplan, Erica Dermer @celiacandthebeast, Katherine Wald and Christine Olivo @myibslife. This was funded by a grant from Ardelyx. We will all be sharing our perspectives about the conference in a blog or video in the coming weeks. I will also be summarizing the scientific insights that I learned in the next few weeks and posting it on our website forums. I have been busy lining up podcasts and webinars with our Tuesday Night IBS (TNIBS) educational partner for the rest of this year. This is what we have lined up. A Tuesday Night IBS podcast will be dropping today about the interview I had with Dr. Alex Ford gastroenterologist from Leeds, UK on his recent clinical ATLANTIS trial for amitriptyline and TRITON trial for ondansetron looking at efficacy in management of IBS-D. This is a must listen for any diarrhea predominant patients who feel that they have run out of options. On July 16th Tuesday Night IBS will be hosting a live webinar about IBS-C and Pelvic Floor Dysfunction. Details are below and on the Tuesday Night IBS website. I will be attending Food: The Main Course conference in Ann Arbor, MI in early August with leading GI Dietitians. I'll be recording a TNIBS podcast with the event organizers about how diet can perhaps help manage IBS symptoms. Later in August, I will be recording a podcast related to Probiotics and IBS. On September 24th I will be moderating a webinar about all of the pharmaceutical treatments available for IBS-C with two gastroenterologists. In October, we will be discussing the IB-Stim device for treating functional abdominal pain associated with IBS in patients 11-18 years of age. I am excited to host this first TNIBS pediatric discussion. In November, our final webinar for this year will host a Nurse Practitioner and IBS-C patient in an interview style discussion about living with IBS-C. We have a busy few months planned and I hope you can either attend or view our webinars and podcasts scheduled. Our community website forums are pretty active right now. If you have a question about how to approach your individual situation the forums are a great place to look for, or get some answers. Finally, I was humbled to be named as a finalist for the 2024 Social Health Awardsin the Lifetime Achievement category. Community health support means a lot to me and I'm thrilled to be recognized with all the others in this category. I hope everyone has a pleasant summer. Sincerely, Jeffrey Roberts, MEd, BSc Founder, IBS Patient Support Group and World IBS Day, April 19th Co-Founder Tuesday Night IBS www.ibspatient.org The July free webinar for patients and providers on July 16th is titled IBS-C and Pelvic Floor Dysfunction. Hear from Dr. Leila Neshatian, MD from Stanford University and Dr. Caryn Phillips PT, DPT a Boston-based Physiotherapist. Both focus their practices on patients with pelvic floor dysfunction which could contribute to worsening constipation and IBS-C symptoms. This program is designed to meet the learning needs of patients and providers alike. Thanks to Ardelyx for their support through an independent educational sponsorship. Click below to register for this free webinar. https://tinyurl.com/IBSCPelvicFloor Check out more upcoming webinars and events, or view any that you missed, on the Tuesday Night IBS website. IBS News Highlights Safety and efficacy of linaclotide in children aged 7-17 years with irritable bowel syndrome with constipation Unmet needs of drugs for irritable bowel syndrome and inflammatory bowel diseases: interest of vagus nerve stimulation and hypnosis A follow-up study of anxiety and depressive symptoms in irritable bowel syndrome Gastroenterologists Swear By These Home Remedies for IBS Pain More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations My Childhood Was Isolated Thanks To IBS — Here's Why We Need To Normalise Talking About Poo Medicines Aren’t Very Effective for IBS: Scientists Found What Works Better I'm a dietician with IBS – and this is how I learnt to identify my dietary triggers Study finds personalized antibiotics, prebiotics, and probiotics combo may help treat IBS Endoscopic Removal of Intrauterine Contraceptive Device From the Descending Colon: A Case Report Rethinking the Low FODMAP Diet for IBS-D Digital Behavioral Therapy Apps Provide More Choices to Patients With IBS Getting past ‘It’s IBS’ Keys to IBS care: Understanding medical options, where they ‘might be most effective’ - Healio Satisfaction With Life in IBS Is Associated With Psychological Burden Rather than Gastrointestinal Symptom Severity How to Have Better Sex With IBS If Your Symptoms Always Hit at the Worst Time Putting Patients First: Breaking Stigma, Dispelling Misconceptions to Improve IBS Care New book a 'holistic toolbox' of nutritional, behavioral strategies for treating IBS Exploring Probiotics for IBS Treatment If you would like to read more IBS News you can find it here If you don't want to miss any newsletters you can join the email list here: https://www.ibspatient.org/resources/newsletter-signup/
  10. I was an alcoholic for a good number of years before being sober for 8 and then getting IBS-C. I just started taking Linzess and was able to get approved for a 90-day prescription for $30. Weird thing was that by the time I got approved got to my pharmacy for pick up, they said my insurance provider came through and the cost was $0. The first time I tried to buy it the cost was $516.
  11. Been using it for almost 2 years. Yea it works but it's kinda intense. My symptoms were so painful and varied that I think I overdid it and weakened my defecation reflex/pelvic floor muscles. I was going down in magnesium (Dulcolax at one point) but not anymore. I'm hoping PT can save me. Just be careful
  12. milbourneian

    Older Woman, newly diagnosed

    Hi Betty, I just came across your post from Apr last year, you mentioned you had problems in the morning - if your diarreah is worst when your stomach is empty for a while you should look into the symptoms/test for gastrinoma - I had those symptoms and was 7 years before diagnosed. Hope this helps
  13. World J Clin Cases. 2024 Jun 16;12(17):3094-3104. doi: 10.12998/wjcc.v12.i17.3094. ABSTRACT BACKGROUND: The mucosal barrier's immune-brain interactions, pivotal for neural development and function, are increasingly recognized for their potential causal and therapeutic relevance to irritable bowel syndrome (IBS). Prior studies linking immune inflammation with IBS have been inconsistent. To further elucidate this relationship, we conducted a Mendelian randomization (MR) analysis of 731 immune cell markers to dissect the influence of various immune phenotypes on IBS. Our goal was to deepen our understanding of the disrupted brain-gut axis in IBS and to identify novel therapeutic targets. AIM: To leverage publicly available data to perform MR analysis on 731 immune cell markers and explore their impact on IBS. We aimed to uncover immunophenotypic associations with IBS that could inform future drug development and therapeutic strategies. METHODS: We performed a comprehensive two-sample MR analysis to evaluate the causal relationship between immune cell markers and IBS. By utilizing genetic data from public databases, we examined the causal associations between 731 immune cell markers, encompassing median fluorescence intensity, relative cell abundance, absolute cell count, and morphological parameters, with IBS susceptibility. Sensitivity analyses were conducted to validate our findings and address potential heterogeneity and pleiotropy. RESULTS: Bidirectional false discovery rate correction indicated no significant influence of IBS on immunophenotypes. However, our analysis revealed a causal impact of IBS on 30 out of 731 immune phenotypes (P < 0.05). Nine immune phenotypes demonstrated a protective effect against IBS [inverse variance weighting (IVW) < 0.05, odd ratio (OR) < 1], while 21 others were associated with an increased risk of IBS onset (IVW ≥ 0.05, OR ≥ 1). CONCLUSION: Our findings underscore a substantial genetic correlation between immune cell phenotypes and IBS, providing valuable insights into the pathophysiology of the condition. These results pave the way for the development of more precise biomarkers and targeted therapies for IBS. Furthermore, this research enriches our comprehension of immune cell roles in IBS pathogenesis, offering a foundation for more effective, personalized treatment approaches. These advancements hold promise for improving IBS patient quality of life and reducing the disease burden on individuals and their families. PMID:38898868 | PMC:PMC11185378 | DOI:10.12998/wjcc.v12.i17.3094 View the full article
  14. Food Funct. 2024 Jun 20. doi: 10.1039/d4fo01087f. Online ahead of print. ABSTRACT Lactobacillus plantarum AR495 is a widely used probiotic for the treatment of various digestive diseases, including irritable bowel syndrome (IBS). However, the specific mechanisms of L. plantarum AR495 in alleviating IBS remain unclear. Abnormal intestinal tryptophan metabolism can cause disordered immune responses, gastrointestinal peristalsis, digestion and sensation, which is closely related to IBS pathogenesis. The aim of this study is to explore the effects and mechanisms of L. plantarum AR495 in regulating tryptophan metabolism. Primarily, tryptophan and its related metabolites in patients with IBS and healthy people were analyzed, and an IBS rat model of acetic acid enema plus restraint stress was established to explore the alleviation pathway of L. plantarum AR495 in tryptophan metabolism. It was found that the 5-HT pathway was significantly changed, and the 5-HTP and 5-HT metabolites were significantly increased in the feces of patients with IBS, which were consistent with the results obtained for the IBS rat model. Maladjusted 5-HT could increase intestinal peristalsis and lead to an increase in the fecal water content and shapeless stool in rats. On the contrary, these two metabolites could be restored to normal levels via intragastric administration of L. plantarum AR495. Further study of the metabolic pathway showed that L. plantarum AR495 could effectively reduce the abundance of 5-HT by inhibiting the expression of enterochromaffin cells rather than promoting its decomposition. In addition, the results showed that L. plantarum AR495 did not affect the expression of SERT. To sum up, L. plantarum AR495 could restore the normal levels of 5-HT by inhibiting the abnormal proliferation of enterochromaffin cells and the excessive activation of TPH1 to inhibit the intestinal peristalsis in IBS. These findings provide insights for the use of probiotics in the treatment of IBS and other diarrheal diseases. PMID:38899520 | DOI:10.1039/d4fo01087f View the full article
  15. Janer

    Janer

    I have constant bloating from ibs, have been told to take probiotic, can anyone suggest one that helps? Been taking kefir but no improvement
  16. Honey at greater than 1 tsp is high FODMAP irrespective if it is Manuka or not. And IBS is not an inflammatory disorder
  17. I had surgery 2 1/2 weeks ago, it went well, healing nicely. I've had a flare up of IBS D for almost 2 weeks. All my usual tools aren't working. My mood is REALLY bad. I have no questions, just need to vent to ppl who get it.
  18. Nutrients. 2024 May 23;16(11):1592. doi: 10.3390/nu16111592. ABSTRACT INTRODUCTION: Irritable bowel syndrome (IBS) symptoms can be effectively managed with the low FODMAP diet. However, its efficacy in reducing inflammation is not yet proven. On the contrary, the Mediterranean diet has anti-inflammatory properties with proven efficacy in treating chronic low-grade inflammation-related diseases. AIM: To publicly share our protocol evaluating the efficacy of the Mediterranean low-FODMAP (MED-LFD) versus NICE recommendations (British National Institute for Health and Care Excellence) diet in managing IBS symptoms and quality of life. MATERIALS AND METHODS: Participants meeting the Rome IV criteria will be randomly assigned to MED-LFD or NICE recommendations and they will be followed for six months. Efficacy, symptom relief, quality of life and mental health will be assessed using validated questionnaires. In addition, fecal samples will be analyzed to assess gut microbiota, and to measure branched and short-chain fatty acids, and volatile organic compounds (metabolic byproducts from bacteria). Expected results and discussion: By publicly sharing this clinical study protocol, we aim to improve research quality in the field of IBS management by allowing for peer review feedback, preventing data manipulation, reducing redundant research efforts, mitigating publication bias, and empowering patient decision-making. We expect that this protocol will show that MED-LFD can effectively alleviate IBS symptoms and it will provide pathophysiology insights on its efficacy. The new dietary pattern that combines the LFD and the MED approaches allows for the observation of the synergistic action of both diets, with the MED's anti-inflammatory and prebiotic properties enhancing the effects of the LFD while minimizing its limitations. Identifier in Clinical Trials: NCT03997708. PMID:38892525 | DOI:10.3390/nu16111592 View the full article
  19. Nutrients. 2024 May 31;16(11):1727. doi: 10.3390/nu16111727. ABSTRACT CONTEXT: Short-chain fatty acids (SCFAs) have been reported to be associated with the pathogenesis of irritable bowel syndrome (IBS), but the results are conflicting. OBJECTIVE: Here, a systematic review of case-control studies detecting fecal SCFAs in IBS patients compared with healthy controls (HCs) and self-controlled studies or randomized controlled trials (RCTs) investigating fecal SCFA alterations after interventions were identified from several databases. DATA SOURCES: A systematic search of databases (PubMed, Web of Science, and Embase) identified 21 studies published before 24 February 2023. Data extractions: Three independent reviewers completed the relevant data extraction. DATA ANALYSIS: It was found that the fecal propionate concentration in IBS patients was significantly higher than that in HCs, while the acetate proportion was significantly lower. Low-FODMAP diets significantly reduced the fecal propionate concentration in the IBS patients while fecal microbiota transplantation and probiotic administration did not significantly change the fecal propionate concentration or acetate proportion. CONCLUSIONS: The results suggested that the fecal propionate concentration and acetate proportion could be used as biomarkers for IBS diagnosis. A low-FODMAP diet intervention could potentially serve as a treatment for IBS while FMT and probiotic administration need more robust trials. PMID:38892659 | DOI:10.3390/nu16111727 View the full article
  20. Martha Carlin, CEO of The BioCollective, discusses the link between the gut microbiome and Parkinson's disease. She emphasizes the significance of mannitol-producing bacteria for treating Parkinson's-related constipation and managing blood sugar. Additionally, she touches on the impact of environmental toxins and the necessity of regular bowel movements for detoxification, stressing the pivotal role of gut health in overall well-being on The Perfect Stool Podcast with host Lindsey Parsons, EdD. Listen below or find the podcast version at: https://link.chtbl.com/theperfectstool-IBS
  21. 8Grandkids

    Bile acid malabsorption (BAM)

    I am 76. Had my gall bladder out in 2020. 6 months after I started having IBSD issues. 3 Gastroenterologists later I was still suffering. Finally my PCP prescribed cholestyramine. The right dosage took a while. But it helped. Didn’t realize you had to stay on it forever. Question? Does anyone have incontinence and urgency? It’s awful. Humiliating. Embarrassing. ☹️
  22. Neurogastroenterol Motil. 2024 Jun 17:e14845. doi: 10.1111/nmo.14845. Online ahead of print. ABSTRACT BACKGROUND: A diet low in fermentable oligo-, di-, monosaccharides and polyols (LFD) improves symptoms in patients with irritable bowel syndrome (IBS). Previous studies have focused on patients with IBS and diarrhea (IBS-D). It is unclear whether LFD is effective for IBS with constipation (IBS-C) or IBS with mixed bowel habits (IBS-M). This open-label, real-world study evaluates the relative effectiveness of the LFD among IBS subtypes. METHODS: This study analyzes data from a service that provides low-FODMAP meals to individuals with IBS. Participants met with a registered dietitian and completed the IBS symptom severity survey (IBS-SSS) before and after undergoing a 2-4-week period of FODMAP restriction. The primary endpoint was the proportion of participants with ≥50-point decrease in IBS-SSS between the three IBS subtypes. KEY RESULTS: After FODMAP restriction, 90% of participants with IBS-D, 75% with IBS-C, and 84% with IBS-M met the primary endpoint (p = 0.045). Similar improvement was seen for a 100-point decrease, but the difference between IBS subtypes was not significant (p = 0.46). After FODMAP restriction, all groups had statistically significant improvement in total IBS-SSS as well as individual symptom categories. Improvement in IBS-SSS subcategories was similar among the groups except for the categories of bloating severity (IBS-M had greatest improvement) and bowel movement satisfaction (IBS-C had less improvement). CONCLUSION & INFERENCES: Though the proportion of responders was highest for IBS-D and lowest for IBS-C, the LFD led to robust improvement in overall symptoms in all IBS subtypes. Key individual symptoms also showed significant improvements in all IBS subtypes. PMID:38887150 | DOI:10.1111/nmo.14845 View the full article
  23. Front Psychol. 2024 Jun 3;15:1389911. doi: 10.3389/fpsyg.2024.1389911. eCollection 2024. ABSTRACT Irritable bowel syndrome (IBS) is a frequent health condition which can be associated with functional disability and reduced health-related quality of life. IBS is classified as a disorder of the brain-gut axis. IBS is a very heterogenous condition with regards to the underlying pathophysiological mechanisms, the clinical picture and the amount of functional impairment. Within a biopsychosocial model of IBS psychosocial factors can play a role in the in the predisposition, triggering and development of chronicity. Somatic or psychosocial or a mixture of both factors might predominate in an individual patient. Gut-directed hypnosis is a special type of medical hypnosis combining standardised gut-directed suggestions (hypnosis) with suggestions tailored to the psychological characteristics of the patient (hypnotherapy). Of brain-gut behavioral therapies, cognitive bahvioral-based interventions and gut-directed hypnosis have the largest evidence for both short-term and long-term efficacy in controlled trials for IBS and are recommended by current European and North American gastroenterology guidelines as second line treatment options. Standardised gut-directed hypnosis is available by audiotapes and can be part of a multicomponent self-management approach by digital health applications. It can be used - based on the patient's preferences-as first line therapy for mild forms of IBS. Severe forms of IBS require face-to-face interdisciplinary management. Standardised gut-directed hypnosis and hypnotherapy tailored to the individual patient can be part of this approach. PMID:38887623 | PMC:PMC11181908 | DOI:10.3389/fpsyg.2024.1389911 View the full article
  24. ..hello, new to site with questions re taking Linzess. Two yrs ago I had my sigmoid colon removed due to chronic diverticulitis. Since then I’ve experienced chronic constipation. I was prescribed Linzess first the 72mcg then the 145 and finally the 290. It certainly works but after the initial blast off I have 3 or 4 revisits with watery stool. The diarrhea after shocks are much better than constipation but I’m concerned about dehydration and loss of electrolytes. First question..is the after shock watery stools normal with the 290 dosage? And secondly how much water does one drink when taking Linzess? I normally drink 10 or 12 ozs early AM on an empty stomach and eat roughly 3 hrs after taking. Thanks in advance for your feedback!
  25. Daniel

    My journey with IBS-C

    My primary care doctor said all my numbers have improved (i.e., sugars and triglycerides were down and HDL was up), so he was ok with my diet changes and supplementation; although, he admitted to not practicing alternative medicine and was not familiar with Dr. Gundry's work. While my vitamin D levels were normal, he agreed to increase my vitamin D from 50,000 IU twice a month to weekly as Dr. Gundry aims for levels of 100-150 NG/mL on blood tests. Also, I just came across this Introduction to Intestinal Permeability (hello.vibrant-wellness.com/hubfs/Clinical/Intestinal-Permeability-For-Patients.pdf) on the VibrantWellness website this morning and thought I would share it with you. Good luck!
  1. Load more activity
×
×
  • Create New...